Contreras-Zárate M, Contreras-Zárate JI, Gómez–García A, Cruz-Balandrán J, Rodea-Hernández SR

Idioma: Español
Referencias bibliográficas: 27
Paginas: 58-63
Archivo PDF: 86.17 Kb.

RESUMEN

Introducción: La enfermedad coronaria (EC) es la principal causa de muerte en México. La homocisteína (HCY), ácido úrico (AU) y el colesterol (c-HDL) se conocen como factores independientes de riesgo para enfermedad cardiovascular. Objetivo: Investigar la relación entre HCY, AU y c-HDL en pacientes con enfermedad coronaria. Material y métodos: Estudio transversal comparativo en 75 pacientes con EC, sin diuréticos, alopurinol, ácido fólico, complejo B y sin enfermedad renal o tiroidea. A cada paciente se le colectó muestra venosa para cuantificación de HCY, AU, glucosa y perfil de lípidos. El análisis estadístico se realizó en SPSS V18. Resultados: Edad promedio: 60.96 ± 16.22 años, 58.45% tuvieron diabetes mellitus tipo 2 (DM2) y/o hipertensión arterial sistémica (HTA). Los pacientes se distribuyeron en dos grupos: AU ≥ 7 mg/dL y AU ‹ 7 mg/dL; se encontraron diferencias en HCY, c-HDL, tensión arterial sistólica y diastólica (p ‹ 0.05). AU correlacionó con c-HDL (r = -0.307; p = 0.010) y HCY con c-HDL (r = -0.283; p = 0.019). Por regresión lineal se encontró HCY como factor predictor del AU (coeficiente estandarizado β: 0.294; t: 2.458; p = 0.017) y de c-HDL (coeficiente estandarizado β: 0.269; t: 2.232; p = 0.029). Conclusiones: Existe relación entre AU y HCY con c-HDL. La HCY es factor predictor de hiperuricemia y de baja c-HDL en pacientes con EC. Se recomienda incluir la HCY como determinación de rutina en pacientes de alto riesgo, historia familiar y/o EC prematura.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Chilton RJ. Pathophysiology of coronary heart disease. JAMA 2004; 104: S5-S8.

2. Álvarez AC, Leyva-Jiménez R, Gómez-García A. Relación entre la hiperhomocisteinemia y la insuficiencia renal crónica. Ciencia Nicolaita 2005; 40: 77-90.

3. Stampter MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 887-889.

4. Clarke R, Daly L, Robinson K, Naughten E et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.

5. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995; 274: 1049-1057.

6. Heijer M, Hoster T, Blom JH, Bos MJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.

7. Willinek WA, Ludwing M, Lennarz M, Holler T, Stumpe OK. High-normal serum homocysteine concentrations are associated with an increased risk of early atherosclerosis carotid artery wall lesions in healthy subjects. J Hypertens 2000; 8: 425-430.

8. Niggard O, Vollset SE, Refsum H, Stevensvold I et al. Total plasma homocysteine and cardiovascular risk profile. JAMA 1995; 274: 1526-1533.

9. Verhoef P, Hennekens CH, Allen RH et al. Plasma total Homocysteine and a risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997; 79: 799-805.

10. Nyggard O, Nordrehaug JE, Refsum H et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-235.

11. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526-2532.

12. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87: 1411-1414.

13. Letho S Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-639.

14. Schretlen DJ, Inscore AB, Vannorsdall TD et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423.

15. Roberts JM, Bodnar LM, Lain KY et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension 2005; 46: 1263-1269.

16. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.

17. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007; 27: 435-440.

18. Navarro LF. Bases genéticas de la enfermedad coronaria. Rev Esp Cardiol 2002; 55: 413-431.

19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL; and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-2572.

20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection Evaluation and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation 2002; 106: 343-421.

21. Feig DI, Kang DH, Johnson RJ. Ácido úrico y riesgo cardiovascular. N Engl J Med 2008; 359: 1811-1821.

22. Cuneo C. Lipoproteínas de alta densidad y enfermedad coronaria. Rev Fed Arg Cardiol 2001; 30: 103-111.

23. Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein colesterol. Am J Cardiol 1998; 82: 13Q-21Q.

24. Xiao Y, Zhang Y, Lv X, Su D et al. Relationship between lipid profiles and plasma total homocysteine, cysteine and the risk of coronary artery disease in coronary angiographic subjects. Lipid Health Dis 2011; 10: 137-142.

25. Soinio M, Marniemi J, Laakso M, Letho S, Rönnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004; 140: 94-100.

26. Kannani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1997; 95: 1119-1121.

27. Saavedra WF, Paolocci N, St John ME et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90: 297-304.